MedTrace Logo

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1083

Last updated 2013-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Conditions

Interventions

DRUG

Bazedoxifene/Conjugated Estrogen

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

DRUG

Bazedoxifene/Conjugated Estrogen

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

DRUG

CE 0.45 mg/MPA 1.5mg

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

OTHER

Placebo

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242710 on ClinicalTrials.gov